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 Transition metal compounds have been shown to be insulin-enhancing but the 
mechanism of action has not been fully elucidated.  With obesity, diabetes and other metabolic 
derangements increasing in developed countries, understanding the effects these compounds will 
better target drug therapy.  Previous investigations have focused on vanadium and have studied 
the effects on protein-protein interactions in the insulin signaling pathway.  In this paper, we 
propose that the mechanism of action may also include interactions with the plasma membrane.  
Lipids as bioactive molecules are on the horizon as the next great area of exploration in 
biochemistry and molecular biology.  Within the insulin signaling pathway, the insulin receptor 
functions optimally in areas of specialized lipid packing that are characterized as small detergent 
insoluble regions enriched in sphingomyelin and cholesterol and termed lipid rafts.  These lipid 
rafts are a subset of microdomains within the plasma membrane.  Obesity and excess lipids have 
been shown to increase inflammation via increases in free fatty acids, cytokines, TNF-α, and 
reactive oxygen species resulting in the peroxidation of membrane lipids.  We propose that one 
cause of insulin resistance, a failure of insulin receptors to respond to insulin, is due to disruption 
of the membrane lipids resulting in an increase in membrane fluidity.  This disruption results in 
displacement of insulin receptors out of specialized lipid rafts.  We propose that treatment with 
vanadium will result in an increase in membrane rigidity favoring lipid raft formation and 
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restoration of insulin receptors to a platform favoring optimal signaling.  Time-correlated single 
photon counting fluorescence anisotropy was used to measure the membrane fluidity of RBL-
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Diabetes mellitus is the leading cause of blindness, amputations, and cardiovascular-
linked death with a post-diagnosis life expectancy worse than some forms of cancer (1).  It is a 
debilitating metabolic disorder characterized by lack of insulin secretion or lack of response to 
insulin resulting in impaired metabolism of carbohydrates, lipids, and proteins.  Type 1 diabetes 
results from the failure of the β-cells of the pancreas to produce insulin and accounts for 5-10% 
of diabetes cases.  Type 2 diabetes, is characterized by insulin resistance, obesity, and 
dyslipidemia, and accounts for 90% of diabetes cases. 
Obesity is one of the most common nutritional disorders in the United States whose 
prevalence has increased more than 75% since 1980 (2).  Defined as a body-mass index in the 
95
th
 percentile or higher for age and sex, obesity is commonly recognized as increased lipid 
accumulation, as a result of nutrient oversupply, and is predicted to lead to a decline in life 
expectancy (3).  Studies of obesity have been extensive due to the deleterious effects of excess 
lipids in the body (4).  Obesity is known to lead to dyslipidemia, insulin resistance, eventually 
leading to the development of Type II Diabetes, and is associated with Metabolic Syndrome. (5-
7).  
While each of the above conditions can exist alone, they are traditionally found 
associated with one another and, due to the metabolic pathways involved, can potentiate the 
effects of one another (8).  Insulin resistance due to obesity is usually a precursor to the 
development of Type II diabetes, which is estimated to exist up to 10 years prior to a formal 
diagnosis (9).  Obese patients are typically found to be hyperglycemic and hyperinsulinemic.  
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The hyperinsulinemia is a result of being in a state of insulin resistance.  The target tissues in the 
body are no longer responsive to the insulin being produced so the body responds by increasing 
the amount of insulin produced by the β cells of the pancreas.  The hyperglycemia exists because 
the tissues are not able to respond to the insulin secreted and therefore have impaired uptake of 
glucose by the target cells.  It has been noted that some individuals have a decreased affinity of 
the insulin receptor (IR) for insulin while others have normal binding of insulin but decreased 
intracellular response with decreased recruitment of the GLUT4 transporter to the cell surface in 
order to transport glucose into the cell (5-7).  
 Along with insulin resistance, obesity is known to produce dyslipidemia, a disruption in 
the amount of lipids in the blood and/or the ratios of lipids found in the blood when compared to 
a healthy individual.  Excess lipids have been shown to accumulate in specialized tissues such as 
muscle, liver and heart (1).  This has been noted in Metabolic Syndrome and Type II diabetes 
with the hallmark of high levels of triglycerides (TGs), increased low density lipoproteins (LDL) 
cholesterol and decreased high density lipoprotein (HDL) cholesterol levels (10).  
Metabolic Syndrome is a cluster of metabolic derangements that include insulin 
resistance, obesity, hypertension, and dyslipidemia (9).  While Metabolic Syndrome has received 
a great deal of attention, there is a lack of consensus as to whether metabolic syndrome actually 
constitutes its own diagnosis or is simply the sum of its parts (11,12).  The treatment of 
metabolic syndrome is to treat each of its parts individually, the hypertension with hypertension 
medications, the insulin resistance with hyperglycemic medications, the dyslipidemia with drugs 
targeting the lowering of TG and LDL and the elevation of HDL’s in the blood stream, hoping to 
prevent or slow the development of Type II diabetes in the patient (13-15).  In order to 
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understand the relationships between excess lipids and the many signaling pathways involved in 
metabolic derangements, we will first look at insulin and the insulin signaling pathway. 
 
THE INSULIN MOLECULE 
Insulin and the insulin-signaling pathway have been extensively studied due to their 
involvement in disease progression and glucose homeostasis.  Insulin is the most potent anabolic 
hormone and is involved in synthesis and storage of carbohydrates, lipids and proteins as well as 
inhibiting degradation and subsequent release into circulation (16).  Specifically, insulin is 
produced in the Islets of Langerhans in the pancreas by the β-cells and is composed of 51 amino 
acids.  The action of insulin is mediated by the insulin receptor.   
 
THE INSULIN RECEPTOR 
The insulin receptor (IR) is a tyrosine kinase transmembrane protein.  It consists of two 
α- and two β-subunits bound by disulfide bonds.  Upon insulin binding to the α- subunit on the 
extracellular surface of the cell, a conformational change occurs which results in ATP binding 
the β-subunit’s intracellular domain (18).  The β-subunit has extracellular, transmembrane and 
cytosolic regions.  Upon ATP binding, autophosphorylation occurs on the cytosolic domain on 
three clusters of tyrosine residues (19).  Once phosphorylated, the IR catalyzes the 
phosphorylation of several intracellular targets such as, insulin receptor substrate protein 1 (IRS-






Figure 1. Molecular structure of insulin.  Shown here in its primary structure showing the 
alpha and beta chains with disulfide bridges, a three dimensional representation and as a hexamer 








Figure 2. Computer generated 3-D modeling of the insulin receptor structure.  Also 
shown is the relative size of the insulin molecule and its orientation in the receptor when binding.  
The insulin receptor has an extracellular domain which binds insulin, a transmembrane domain 
(labeled) which crosses the cell’s plasma membrane, and a cytoplasmic domain (represented in 
green) which contains the portion of the receptor that undergoes autophosphorylation upon 






THE INSULIN SIGNALING PATHWAY 
When considering the insulin signaling pathway shown in Figure 3, attention must be 
paid to each site of phosphorylation. Sites of phosphorylation may serve as points of potential 
regulation.  Signaling proteins with Src homology (SH2) domains are recruited by those targets 
and interact with the sequences surrounding the phosphotyrosines. Specific to IRS-1 family 
members is the generation of a docking site for p85, a regulatory subunit of type 1A 
phosphatidylinositol 3-kinase (PI3K) (18,21).  PI3K phosphorylates phosphatidylinositol-4,5P2 
(PIP2) to generate phosphatidylinositol-3,4,5-triphosphate (PIP3).  PIP3 acts as the allosteric 
regulator of phosphoinositide-dependent kinase (PDK1), which phosphorylates and activates Akt 
and atypical protein kinase C isoforms PKCζ and PKCλ (22).  PKC’s are responsible for 
generating glucose uptake via the GLUT-4 transporters in muscle cells and adipocytes.  While 
Akt and PI3K are known to play a role in GLUT4 translocation, there exists a PI3K independent 
pathway for GLUT4 recruitment. Cbl phosphorylation via insulin, associates with the CAP 
adaptor protein.  This causes the Cbl-CAP complex to translocate to lipid rafts, or microdomains 
(MDs) in the plasma membrane.  These will be discussed later in detail.  At the MD, Cbl 
interacts with Crk, an adaptor protein, which is constitutively associated with the Rho-family 
guanine nucleotide exchange factor C3G. C3G activates TC10, a member of the GTP-binding 
protein family, which promotes GLUT4 translocation to the plasma membrane (23).  Akt can 
activate 1) glycogen synthesis through glycogen synthase kinase 3 (GSK3), 2) gene expression 
through FKHR, and 3) protein synthesis by p70S6K (18).  GSK3 acts on glycogen synthase, an 
enzyme that catalyzes the last step in glycogen synthesis.  Once GSK3 phosphorylates glycogen 
synthase, it has effectively inhibited glycogen synthesis.  Therefore, Akt inactivation of GSK3 
promotes glucose storage as glycogen.  Through phosphorylation and dephosphorylation events, 
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insulin blocks gluconeogenesis and glycogenolysis by the liver by controlling the expression of 
certain genes that encode for specific proteins required for gluconeogenesis (23).  Synthesis of 
lipids is also controlled by insulin, as well as their degradation.  This occurs through the 
transcription factor steroid regulatory binding protein SREBP-1.  In adipocytes, glucose is stored 
as lipid and insulin inhibits lipolysis by blocking lipase, an enzyme sensitive to the hormone (23).  
Having discussed the cellular targets interactions and functions for insulin binding the IR, the 
insulin receptor can bind more than just insulin. 
One of the unique features of the insulin receptor is its ability to bind insulin-like growth 
factor (IGF-1 and IGF-2).  The affinity for binding these ligands is 100-1000 times lower than 
the receptor’s affinity for insulin, but the circulating concentration of IGF-1 is around 100 times 
higher.  IGF-2 has equal affinity for IRs and its own receptor. IGF-1 and IGF-2 also act by 
phosphorylating tyrosine residues on the IRS family of molecule (18).  Binding of insulin-like 
growth factors leads to a growth response in the cell.  The ability of the IR to bind more than one 
ligand may also be a point of regulation with attention to be paid to the possible changes in 
concentration of ligands in response to the stresses associated with metabolic syndrome.  The 
termination of signals from the IR has been linked to events following ligand dissociation.  
Once insulin dissociates from the receptor, its substrates undergo rapid 
dephosphorylation, which implicates protein tyrosine phosphatases (PTPases) in signal 
termination.  Lipid dephosphorylases can also exert temporal control by dephosphorylating PIP3.  
Vollenweider et al. demonstrated that microinjection of phosphoinositide phosphatase SHIP2, 






Figure 3. The insulin signaling pathway.  Pathway activation can have multiple effects 
including glucose uptake, glucose metabolism, synthesis of glycogen, fats and proteins, and gene 
expression.  Depending on the pathway activated, the response to binding ligand can be varied 
(23).  (Adapted from Saltiel, A. R.; Kahn, C. R. Nature, 2001, 414: 799-806). 
 
INSULIN RECEPTORS LOCALIZE TO MICRODOMAINS 
Key to optimal IR function, is its localization to small membrane regions known as lipid 
rafts, a specialized subset of microdomains (MD) that are enriched in sphingomyelin and 
cholesterol (23,25-27).  Upon binding insulin, the IR’s move into the MDs which serve as 
platforms on the exoplasmic leafs of the lipid bilayer (28).  One of the characteristics of MDs is 
their ability to include or exclude certain proteins selectively, with the affinity for a particular 
protein being influenced by both intra- and extracellular stimuli.  Interactions between adaptors 
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and scaffold and anchoring proteins can be organized through microdomains to transduce the 
signal leading to amplification through signal molecule concentration and the exclusion of 
unwanted modulators (29).  Interestingly, MDs and their interactions with IRs in the insulin-
signaling pathway can vary according to the tissue type involved.  In adipocytes, IRs associate 
with a subset of MDs known as caveolae as seen in Figure 4 (29,30).   
 
 
Figure 4. Insulin receptors associated with caveolin-enriched caveolae, a subset of 
microdomains. Caveolae may or may not be required for all insulin signaling, depending upon 
the tissue of interest, but a general microdomain enriched in cholesterol and sphingomyelin is 
required. The relationship between IR distribution and insulin resistance in response to 
inflammation is also shown (31). (Adapted from Kabayama et al. Glycobiology 2005, 15: 21-29.) 
Caveolae are small, flask shaped, non-clatharin-coated invaginations in the plasma 
membrane (PM) that are rich in the protein caveolin (32,33).  Caveolin also associates with the 
GLUT4 glucose transporter in adipocytes (33).  Though found intracellularly, caveolin in the PM 
exists only in caveolae, whose proper function depends on a sufficient level of cholesterol (34).  
However, in the liver, the IR does not require calveolae within the MD, in order to function 
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properly, though it is still associated with a lipid raft region in the plasma membrane that is 
enriched with cholesterol (28).  The variability of the localization of the IR, based on tissue 
distribution, implies that the features that regulate responses through IRs in MDs are specialized.  
In order to understand the specialized role that MDs play in signaling, we must understand the 
distribution of lipids within the PM. 
 
CELL MEMBRANE COMPOSITION 
The plasma membrane has been a subject of study for many years.  Basic science 
textbooks include descriptions of the fluid mosaic model of the membrane first proposed by 
Singer and Nicolson in 1972 which described a bilayer of lipids with different proteins scattered 
throughout (35).  Since then, research has revealed that the PM is more complex and dynamic 
than initially believed.  Heterogeneity exists between the extracellular side of the PM and the 
cytosolic side.  The distribution of phospholipids on the extracellular leaflet has a large 
concentration of phosphatidylcholine (PC) and sphingomyelin (SM).  The cytosolic leaflet is 
preferentially composed of phosphatidylethanolamine (PE) and phosphatidylserine (PS) (36-39).  




Figure 5. Model of a cell’s plasma membrane demonstrating heterogeneity in the 
distribution and location of phospholipid constituents and cholesterol. Various types of 
membrane associated proteins are also modeled as well as the associated cytoskeleton on the 
cytoplasmic side of the plasma membrane bilayer (40).  (Adapted from Pietzsch, J., Nature, 2004, 
Horizon Symposia: Living Frontier, 1-4.) 
The lipid elements of the membrane are initially constructed in the smooth endoplasmic 
reticulum (SER), specifically the glycerophospholipids which are synthesized on the cytoplasmic 
side of the SER.  From the SER, the phospholipids are transferred to the Golgi.  Within the Golgi 
it has been found that the asymmetry of the membrane bilayer is established.  Specific proteins in 
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red blood cells, termed flippases, floppases, and scramblases, have been found to be responsible 
for redistributing and orienting the phospholipids for vesicular transport to the PM so that they 
are appropriately matched for fusion with the PM bilayer (36,37).  Flippases are responsible for 
“flipping” lipids toward the cytoplasmic side of the membrane and floppases move lipids in the 
opposite direction.  Scramblases possess the ability to move lipids in either direction and have 
been found to be involved in apoptosis and cell signaling (41).  In other types of eukaryotic cells, 
similarly functioning proteins have been identified (38, 42-44). 
 
LIPID PACKING 
Within the PM exist specialized regions known as lipid rafts, previously mentioned in the 
section on the insulin signaling pathway.  These subsets of MDs are unique in their composition 
of high concentrations of sphyingomyelin (SM) and cholesterol.  It has been found that 
cholesterol may play a role in phase separations as it prefers to associate with saturated lipids.  
When a lipid is saturated, it lacks conformational changes in its fatty acids resulting in the ability 
to package themselves more closely together.  This packing is described as being “liquid-
ordered” (LO).  The surrounding membrane is considered “liquid-disordered” (LD) as it has a 
larger concentration of unsaturated lipids and thus cannot spatially organize into a tighter 
conformation as seen in Figure 6 (45-48).  
Given the specificity of the distribution of phospholipids to their respective sides of the 
PM bilayer and the specialized function and composition of lipid rafts and lipid packing in MD 
formation, it is important to next examine the effects that obesity and insulin resistance may have 








Figure 6. a). Model of lipid interactions with components distributed in the cell 
membrane including lipid rafts, caveolae, clatharin coated pits and the cytoskeleton. b). 
Representation of lipid packing in lipid rafts and the effects on the level of order in the 
membrane (49).  (Adapted from (Semrau, S., and Schmidt, T., Soft Matter, J. Royal. Soc. Chem. 
2009, 5: 3174-3186.) 
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LIPID RAFT SPHINGOLIPID SYNTHESIS AND CYCLING 
Sphingolipids consist of sphingophospholipids and sphingoglycolipids, and are major 
players in MDs in the plasma membrane even though they only make up a small portion of lipids 
found in the plasma membrane.  As seen in Figure 7, the major component of sphingolipids is 
sphingomyelin (SM) which contains a head group that is either phosphocholine or 
phosphoethanolamine (50).  The structure of SM includes a long-chain saturated or 
monounsaturated fatty acid, a head group, and a sphingosine base backbone. In the smooth 
endoplasmic reticulum (SER), de novo synthesis of SM occurs.  Ceramide formation begins with 
the synthesis of sphinganine followed by the transfer of an acyl group, this forms 
acylsphinganine (dihydroceramide).  This product is oxidized to form ceramide.  Then the 
phosphocholine head group is attached by SM synthase. SM can be turned over by removal of 
the head group by sphingomyelinases (SMases) and the removal of amide-linked fatty acid by 
ceramidases.  While de novo synthesis of ceramide has already been mentioned, of interest is its 
involvement in the SM pathway, which involves the hydrolysis of SM to form ceramide.  
Ceramide levels have been shown to be elevated in numerous rodent and human models with 
insulin-resistance (51).  Ceramide has also been shown to be pro-apoptotic as de novo Fas 
activated pathway activates PP1, a ceramide-activated Ser-Thr phosphatase.  PP1 then 
dephosphorylates proteins that regulate RNA splicing which results in a pro-apoptotic mRNAs 
being favorably translated (52).  Thus de novo synthesis, as well as SM hydrolysis, is important 




Figure 7.  Sphingolipid synthesis and degradation cycle.  Ceramide has been identified as 
a key player in the production and degradation of sphingomyelin and is shown in dark blue.  This 
may serve a marker for lipid cycling or peroxidation (52).  (Adapted from Hannun et al. 
Molecular Cell Biology 2008, 9: 139-150). 
In the SM pathway, SMases, as mentioned, are responsible for the removal of the 
phosphocholine head group on SM.  SMAses exist as acidic, neutral, or alkaline SMases and are 
localized based on their optimal pH.  Acidic SMases exist in lysosomes whereas neutral and 
alkaline SMases are located in or near the PM.  Ceramide, itself, can inhibit SMase activity.  SM 
synthase catalyzes the reverse reaction of SMases by increasing the rate at which 
phosphorylcholine is transferred from PC to ceramide to yield diacylglycerol (DAG) and SM 
(50).  Ceramide can vary in chain length and can be broken down into sphingosine and a free 
fatty acid (FFA) via ceramidase (CDase).  Sphingosines produced by CDases can be 
phosphorylated by sphingosine kinase to produce sphingosine 1-phosphate (S1P).  S1P has been  
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shown to oppose the action of ceramide (53).  However, this pathway can be manipulated by an 
excess of lipid. 
 
EFFECTORS OF INSULIN SIGNALING AND LIPID RAFT COMPONENTS  
Metabolic derangements, triggered by high-calorie diets and a lack of exercise, are 
associated with increased adipocyte proliferation and inflammation.  Inflammation can affect cell 
signaling pathways through a number of mechanisms.  Mechanisms include production of 
inflammatory cytokines and increasing oxidative stress resulting in an imbalance in regulation of 
the cell’s redox chemistry.  This imbalance results in production of reactive oxygen species 
(ROS) (54).  ROS generation leads to increases in free fatty acids (FFAs) by interacting with the 
cell membrane and oxidizing lipid components which is known as lipid peroxidation.  How these 
mechanisms overlap both the insulin signaling pathway and lipid metabolism is of great interest 
in trying to elucidate the mechanisms of action of potential drugs and for targeting drug therapy. 
Excess lipids have been linked to inflammation resulting in the activation of 
inflammatory cytokines (56).  One such cytokine that has received a lot of attention is TNF-α 
(Figure 8).  TNF-α is produced at greater levels by the excess adipose tissue in obese individuals 
as well as the protein resistin which together both act to impair IR function.  TNF-α can activate 
serine threonine kinases like JNK and IKKβ, already previously mentioned as IRS inhibitors in 
the insulin signaling pathway.  TNF-α can not only inhibit IRS function, it has been shown to 
affect the transcription of cytokine signaling-3, a protein that interacts with the IR and IRS 






Figure 8.  Inflammation and lipid peroxidation. Multiple pathways are involved in lipid 
peroxidation and degradation in response to inflammatory cytokines or ionizing radiation. Of 
note is the formation of ceramide which is implicated in multiple pathways including the 
arachidonic acid pathway which produces leukotrienes and thromboxanes, both of which 
contribute to the pro-inflammatory and pro-thrombotic states found in insulin dysregulation (55).  
(Adapted from the Merk Biosciences website, www.merckbiosciences.co.uk). 
However, these are not the only ways in which TNF-α can act. A study by Kabayama et 
al, showed that TNF-α induces an overproduction of GM-3 ganglioside (57).  This over-
production leads to an insulin-resistant state by GM-3s displacement of the IR from the MDs 
(57).  This suggests that there may be some preferential interaction with the lipids of the MD that 
GM-3 may possess over the IR. Another way in which TNF-α affects MDs is that it alters the 
rates of lipid hydrolysis by rapidly increasing the amount of ceramide produced by breaking 
down SM as well as promoting de novo synthesis of ceramide as well (58-60).  The equilibrium 
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that exists in sphingolipid metabolism between formation of SM or hydrolysis to ceramide raises 
the question that if ceramide levels have been shown to be elevated in insulin-resistant models, 
and IR loss of function can be linked to its association, or lack thereof, with MDs, is the 
hydrolysis of SM to ceramide one cause of what has been seen? While ceramide has been 
implicated in effects on Akt(PKB) and subsequent inhibition of glucose uptake, a recent study 
found that ceramide can also block actin remodeling.  The inhibition was found to be a result of a 
lack of activation of Rac which decreased GLUT4 translocation (61).  Therefore, an 
inflammatory response by TNF-α, can increase ceramide production and result in attenuation of 
insulin signaling via combinatorial mechanisms.  Increases in ceramide levels likely will result in 
increased enzymatic breakdown by CDases resulting in sphingosine and a FFA.  Free fatty acids 
have also been implicated in a loss of insulin signaling and changes in regulation of lipid 
handling by the cell. 
 
FREE FATTY ACIDS IN INSULIN SIGNALING AND LIPID METABOLISM 
Free fatty acids have also been shown to have a role in insulin-resistance.  Non-esterified 
fatty acids (NEFA) can affect insulin signaling via inhibition of PKB (Akt), thereby blocking 
glucose uptake.  NEFAs can decrease the IRS-1 tyrosine phosphorylation by producing an 
inhibitory Ser
307
 phosphorylation by PKCθ (62). 
Adipocytes are capable of esterifying NEFAs into triglycerides and then sequester the 
triglycerides into lipid droplets (63).  Within adipocytes, elevated FFA plasma levels are sensed 
by nuclear receptors known as peroxisome proliferator-activated receptors (PPARs).  These 
control fatty acid degradation and storage, as well as adipocyte differentiation (54).  Lipid 
chaperones in adipocytes called fatty acid binding proteins (FABPs) coordinate lipid metabolism 
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responses. Interestingly, animals lacking FABP4 and FABP5 exhibited similar fatty acid 
resistance found in human and mouse models similar to the effects of PPARs, as well as 
protection from most features of metabolic syndrome (64,65).  This demonstrates that increased 
free fatty acids can affect lipid metabolism via PPARs and FABPs.  Free fatty acids are produced 
as part of normal lipid metabolism as well as inflammation which can lead to increases in 
oxidative stress . 
 
OXIDATIVE STRESS IN INSULIN SIGNALING AND LIPID METABOLISM 
Oxidative stress (OS) is defined as an oxidant/antioxidant system equilibrium imbalance 
where the oxidant side dominates, and as such, has been implicated in the degeneration of 
conditions associated with diabetes (66).  OS has been shown to decrease pancreatic β-cell 
insulin secretion, as well as impair glucose uptake in muscle and fat as well as decrease 
pancreatic β-cell insulin secretion (67).  Many studies have focused on oxidative stress in 
relation to Type II diabetes, and insulin-resistance, and have found increased levels of OS and 
ROS generated in both rodent and human experiments (68-70).  Cardona et al. demonstrated that 
an increase in oxidative stress occurs in subjects with and without metabolic syndrome when 
given a high fat meal by increasing TG rich lipoprotein plasma levels.  The increase in TGs 
levels lead to increases in free radicals from lipids and ROS (1).  The authors did note that this 
was not the only source of oxidative stress, acknowledging the effects of hyperglycemia which 
results in increased inflammation. They also noted the potential of the mitochondria to produce 
ROSs.  The mitochondria is a primary source of electron and oxygen handling in the cell and has 
also been identified as a source of proteins involved in lipid droplet formation and lipolysis 
regulation (71).  While proteins associated with the mitochondria have some control in lipid 
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metabolism, ROSs can also affect lipolysis by interacting with the cell membrane leading to lipid 
peroxidation.  Antioxidant enzymes have been demonstrated to be part of the regulation of ROS 
in the cell.  ROSs levels elevate with a decrease in antioxidant enzyme concentrations (70).   
Regulation of ROSs includes the antioxidant defense. The antioxidant defense was 
described as a network of enzymes including glutathione peroxidase (GPx), and antioxidants that 
are non-enzymatic.  GPx is a seleno-enzyme, meaning it contains selenium which is required for 
its function. Some of the functions in which GPx is involved are signaling pathways of cell death 
and survival, protein kinase phosphorylation, and oxidant-mediated activation of NFκB as well 
as maintaining lipid peroxide levels (72).  Interestingly, studies described in the review by Lei et 
al. showed that GPx-overexpressing mice developed hyperglycemia, hyperinsulinemia, and 
insulin resistance (72).  This is counter-intuitive as functioning Gpx is part of the antioxidant 
defense.  This implies that the redox chemistry within the cell is in a state of equilibrium in that 
without sufficient GPx, lipid peroxidation proliferates.  How lipid peroxidation affects insulin 
signaling and the cell membrane will be explained next.  
 
LIPID PEROXIDATION IN INSULIN SIGNALING AND LIPID METABOLISM 
Lipid peroxidation occurs when ROS interact with the lipid components of the cell 
membrane. Levels of lipid peroxides were found to be higher in Type 2 diabetics compared to 
controls and Type 1 diabetics in a study by Cymbaljevic et al. (10).  This is likely due to 
increased inflammation, free fatty acids, and oxidaive stress secondary to excess adipose tissue 
seen in Type II diabetics.   
Lipid peroxidation byproducts have recently been implicated in changes in human insulin 
structure and function. Pillon et al. demonstrated that adductions occur at the histidine residues 
21 
 
on the human insulin molecule when exposed to highly volatile lipid peroxidation byproducts.  
They then demonstrated that the efficacy of GLUT4 translocation and subsequent glucose uptake 
was significantly reduced in multiple models including 3T3-L1 adipocytes, L6 muscle cells, and 
the hypoglycemic effects of the modified insulin in mouse models was also significantly 
decreased (73).  In a study done by Navarro et al. hydroxyl radicals introduced carbonyl groups 
to the native insulin molecule as well as tyrosine residue formation.  The changes in the insulin 
molecule also resulted in ineffective glucose uptake in rat models and adipocytes (74).  These 
data add to the growing body of evidence that inflammation and lipids play a large and multi-
factorial role in the development of insulin resistance and diabetes.  Investigations into potential 
therapies should include exploration of effects on both insulin and its pathway as well as any 
effects the potential therapy may have on the membrane. 
 
VANADIUM AND OTHER TRANSITION METAL COMPOUNDS WITH INSULIN 
ENHANCING ACTIVITY AS NOVEL THERAPIES 
 Vanadium was used historically in France as a treatment for diabetes (75).  It is generally 
recognized that insulin responsiveness can be enhanced and elevated blood glucose and lipid 
levels can be normalized.by administration of specific vanadium compounds (76-81).  Other 
transition metal compounds including chromium and molybdenum have also demonstrated 
insulin-enhancing properties both individually or in combination with vanadium (82-86).  
Interestingly, some the vanadium compounds studied did not interact with the insulin receptor 





VANADIUM AND PHOSPHORYLATION 
 One of the mechanisms of actions of certain vanadium compounds is to inhibit 
dephosphorylation by protein tyrosine phosphatases (PTPases) which results in sustained 
phosphorylation of intracellular proteins which then results in a lack of termination of signal.  
The lack of termination in signaling results in perpetuation of signaling (91-98).  This has been 
demonstrated in adipocytes in insulin signaling and is thought to act via PI3K (99).  With BMOV 
treated adipocytes, it was found that in the presence of insulin there was increased 
phosphorylation of the tyrosine residues of the IR as well as increased phosphorylation of IRS-1 
(100).  
 In answer to the question whether it is the vanadium compounds or the ligands that effect 
insulin signaling, several investigations found that certain classes of vanadium compounds are 
found to enhance the activity of insulin with the metal with a greater affect than the ligand alone.  
In recent studies, the effectiveness varies with the oxidation state of the metal (101,102) and the 
various ligands exert a “fine-tuning” effect (79,103) to enhance insulin responsiveness in part by 
decreasing the toxicity of the metal within the body.  A study by Barrand et al. noted that malto 
and ethylmalto ligands provided some protection against the gastrointestinal irritation that 
vanadium compounds can cause (104). 
 
VANADIUM AND REACTIVE OXYGEN AND NITROGEN SPECIES 
 Vanadium compounds have been found to be involved with stress signaling pathways in 
the cell as well as apoptosis (87,105) have also been found to produce ROS and reactive nitrogen 
species (RNS) as well as affect glutathione levels in cells (106-109).  As previously discussed, 
glutathione is involved in the antioxidant/oxidant balance in the cell and diabetes and obesity are 
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linked to increases in ROS generation.  This apparent imbalance changes the redox state of the 
cell.  Vanadium compounds are known to undergo redox cycling within the cell and this may be 
one mechanism of modulating the other players previously identified in the insulin signaling 
pathway.  
 
VANADIUM AND THE PLASMA MEMBRANE 
 While it has been demonstrated that some vanadium compounds exert their effects 
through PTP inhibition within the cell, it is worth examining the interactions of vanadium 
compounds with the PM.  In order to gain access into the cell, vanadium compounds must 
interact with the cell’s membrane.  Recent findings demonstrate that the insulin-enhancing 
compound [VO2dipic] (110,111) penetrates the lipid interface and is located in the hydrophobic 
portion of the lipid layer of the microemulsion (112,113).  Previous reports have shown the 
highly lipophilic vanadium compounds such as naglivan (114) are able to penetrate lipid 
monolayers (81,115).  New evidence suggests that vanadium compounds can also affect 
membrane composition and lipid packing (116,117). 
 It is the seemingly multifactorial effect that vanadium compounds have on the insulin 
signaling pathway that warrants further investigation as to how these molecules exert their 
effects.  In this study, BMOV was used as it is structurally similar to 
bis(ethylmaltolato)oxovanadium (IV) complex (BEOV) that has completed phase 1 clinical trials 
(118).  See Figure 9 for a comparison of the two structures.  What effects, if any, it has on the 
fluidity of the cell membrane may suggest a change in the lipid packing of the PM as a 






 Figure 9. Molecular structure of BMOV and BEOV.  Chemically and structurally, 
BMOV and BEOV are similar.  BEOV began stage II clinical trials in 2008 and differs from 
BMOV by one additional hydro carbon (CH2). Abdol-Khalegh Bordbar et al. noted that much of 
the chemistry involved in the affinity of BMOV for binding human serum transferrin involved 
oxidation of the vanadyl (IV) ion (119).  (Adapted from Abdl-Khaegh Bordbar, A., et al., 
Journal of Inorganic Biochemistry 2009.:103, 643–647.)  
 
ANISOTROPY AS A METHOD OF MEMBRANE FLUIDITY MEASUREMENT 
 Anisotropy uses polarized excitation of a sample and measures the intensity of the 
fluorescence emission through a polarizer.  Polarized light preferentially excites fluorophores 
whose transition moments are aligned parallel to the excitation’s polarization.  The fluorescence 
from these molecules will also be parallel to the excitation.  The mathematical equations for 
anisotropy have been derived by Lakowicz in his work, Principles of Fluorescence Spectroscopy 
(2006). Anisotropy is described mathematically as 
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          (1) 
      
A number of things can affect a measured anisotropy.  For example, rotational diffusion 
of a fluorophore will affect measures of anisotropy by depolarization as the molecules transition 
moment changes.  If the fluorescent molecule has freedom of motion prior to polarized excitation, 
the transition moment of the molecule will not be fixed and thus the probability of the molecule 
being oriented to the polarized excitation is low.  Therefore the fluorophore is not likely to be 
excited. If the molecule is oriented to the polarized excitation and has freedom of motion 
following excitation, the angle at which the fluorophore will emit will not be parallel to the 
excitation polarization (120). 
According to the author of Principles of Fluorescence Spectroscopy, the value for 
anisotropy, r = 1.0, if a single fluorophore is oriented along the z-axis as seen in Figure 10.  
However, the limit of r = 0.4 is based on mathematical derivations from the probability 
distributions for molecules that will display maximal photoselection and is a function of cos
2
θ.  
See Equation 2.  The authors note that any value greater than r = 0.4 is attributed to light scatter 
or multi-photon excitation.  




 Figure 10. Z-axis orientation of the excited state distribution for an immobile fluorophore 
with an anisotropy of r = 0.4 (120).  (Adapted from Lakowicz, J. R. 2006. Principles of 
Fluorescence Spectroscopy. Springer, Berlin, Germany.) 
When considering rotational diffusion, the viscosity of the environment plays an 
important role in how quickly a fluorophore can rotate or diffuse.  When a fluorophore inserts 
itself into the PM, its position becomes fixed and is therefore capable of responding to polarized 
excitation.  The fluidity of the PM can change in the face of changes in the environment of the 
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cell.  When the PM becomes more fluid, the fluorophore is no longer in a fixed position and thus, 
there is a change in anisotropy.  It is the resultant change in anisotropy that describes changes in 
the probe environment.   For our experiments, we chose to use Time Correlated Single 
Photon Counting (TCSPC) Anisotropy.  This method differs from steady state fluorescence 
anisotropy in that fluorescent decays model the photons of light being emitted over a period of 
time following the excitation from a source of light.  Rather than measure every photon emitted 
for each excitation, TCSPC Anisotropy is a method used to detect one and only one photon 
emitted after fluorescence per pulse of light, for many, many pulses of light and is an averaging 
technique (120).  Figure 11 is a detailed schematic of the instrument.  The rationale for this 
method is that a fluorescent probe, when inserted in a lipid bilayer, will not display the typical 
decay to zero used in steady state anisotropy.  It is this principle that demonstrates the restricted 
motion of the probe within a membrane and thus any changes in a timed anisotropy decay will 
yield information on how a treatment has affected the probe’s environment (120).  The equation 
used in evaluating time-dependent decays is   
 
                    (3)    






 Figure 11. Detailed schematic of the Time-correlated Single Photon Counting apparatus 
of the Jovin IBH used in the experiments (121).  Image is courtesy of Laura Swafford of the 
Levinger lab at Colorado State University.  
 
TMA-DPH MEMBRANE PROBE 
 The fluorophore chosen for the fluidity measurements is the dye 1-(4-
trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p-toluenesulfonate, (TMA-DPH) from 
Molecular Probes of Invitrogen.  TMA-DPH is well characterized and has been used extensively 
to explore lipid membrane dynamics and characterization (122-124).  TMA-DPH has a 
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maximum absorbance at 356nm and emits at 435nm.  The carbon chain inserts itself into the 
outer leaflet of the membrane and the trimethylammonium component interacts with the 
polarized environment on the external surface of the cell. 
 
 
Figure 12. Chemical structure of membrane fluorescent probe TMA-DPH.  TMA-DPH: 
is a suitable fluorescence polarization probe for specific plasma membrane fluidity studies in 
intact living cells. TMA-DPH (in blue) locates near the polar heads of phospholipids; anionic 
phospholipids are represented in red and zwitterionic in yellow (125). (Adapted from Ribeiro, M., 







EVALUATING MEMBRANE FLUIDITY USING TIME-CORRELATED SINGLE PHOTON 
COUNTING FLUORESENCE ANISOTROPY  
INTRODUCTION 
As previously established, IR’s function best when clustered in specific microdomains 
within the plasma membrane and are influenced by the lipid packing of the plasma membrane.  
Changes in the fluidity of the PM would imply changes in the lipid packing of the cell.  The goal 
of this project is to investigate the effect on the PM of BMOV treatment in the plasma membrane 
of RBL-2H3 cells.  In order to measure membrane fluidity we will use time-correlated, single 
photon counting fluorescence anisotropy. 
RBL-2H3 cells are well characterized and have well characterized PM’s, specifically 
with Type 1 Fcε receptors.  Multiple studies have described Type 1 Fcε receptor’s lateral 
dynamics and signaling within membrane MDs.  Like the IR, proper signaling requires 
positioning within a MD. (126-130). Therefore RBL-2H3 cells were selected for experimentation.  
 
MATERIALS 
 Minimum Essential Medium (MEM) with Earle’s Balanced Salts was purchased from 
Thermo Scientific (Logan, Utah). Fetal bovine serum (FBS) was purchased from Invitrogen 
(Carlsbad, CA).  L-glutamine, penicillin and streptomycin and amphotericin B, (PSA) were 
purchased from Gemini BioProducts (Woodland, CA).  Insulin from bovine pancreas was 
purchased from Sigma-Aldrich (St. Louis, MO).  BMOV and oxidized BMOV were synthesized 
and characterized as previously described (131-132).  For cell experiments, BMOV was prepared 
fresh before each experiment as a 100x stock solution in phosphate buffered saline (PBS), pH 7.2, 
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by the Crans laboratory.  TMA-DPH and Trypan blue were purchased from Molecular Probes 
Invitrogen (Grand Island, NY).  Ficoll, and EDTA were purchased from Sigma Aldrich, (St. 
Louis, MO).  NaOH and HCl were purchased from Fisher Scientific (Denver, CO).  Doubly 
distilled deionized water with specific resistivity ≥ 17.8 MΩ·cm (Barnstead E-pure system) was 
used throughout.  Eppendorf 2mL tubes were purchased from Sigma Aldrich, (Milwaukee, WI).  
BD Falcon 75mL polystyrene sterile non-pyrogenic flasks and BD Falcon 50mL polypropylene 
conical tubes were purchased from BD Biosciences, (San Jose, CA).  10mm Quartz Fluorometer 
cuvettes were purchased from Starna Cells (Atascadero, CA).  Hemacytometer was purchased 
from Beckman Coulter, (Brea, CA)  RBL-2H3 cells were kindly provided by Dr. Reuben 
Siraganian of the National Institutes of Health.  Instrumentation includes the Jobin IBH Model 
500F with Xenon Flashlamp Fluorometer and LUDOX were purchased from Jobin Yvon IBH 
(Glasgow, UK).  The Zeiss Axiomat microscope equipped with a Zeiss 63x NA 1.2, Plan 
Neofluar immersion fluorescence objective with appropriate Omega dichroic mirrors and filters 
for imaging TMA-DPH fluorescence were purchased from Zeiss (Germany).  The Damon/IEC 
DPR-6000 Centrifuge was purchased from Thermo Scientific (Asheville, NC).  Data analysis 




 RBL-2H3 cells were maintained in RBL-2H3 medium made of 830mL MEM, 150mL FBS, 
10mL PSA, 10mL L-glutamine which was sterilized via vacuum filtration filter.  For serum 
starving cells, a medium was prepared with only 980mL MEM, 10mL and PSA, 10mL L-
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glutamine.  Cells were incubated in ThermoForma Series II Water Jacketed CO2 Incubator with 
Hepa filter at 37°C, 5%CO2 and grown to 90% confluency.  
 
Cell Counting Protocol 
Cells were serum starved overnight.  Control cells were not serum starved.  At 16hrs, 
cells were removed from the incubator.  The medium was removed and discarded and replaced 
with 8mM EDTA (pH 8.0) in 1X PBS to remove cells from the flask.  Cells were washed with 
5mL 1X PBS and transferred to 50mL conical centrifuge tubes.  Cell samples were spun at 1000 
RPM for 3 minutes.  Supernatant was discarded and pellet was suspended in 10mL 1X PBS.  
This cycle was repeated 3 times.  After last spin, supernatant as discarded and pellet was 
suspended in 1xPBS to equal exactly 1mL.  In an Eppendorf tube, 10µL of cells from the 1mL 
suspended pellet solution was placed and 990µL 1X PBS, and 1mL Trypan blue was added.  The 
Eppendorf tube was briefly agitated to insure distribution of the Trypan blue dye.  A Beckman 
Hemacytometer was loaded with 10µL Trypan blue cell mixture on each side and cells imaged 
under microscopy.  Cell viability of 95% was the requirement for continuing with anisotropy 
measurements (124). 
 
Instrument Parameters for Anisotropy Measurements 
The Jovin IBH Fluorometer was programmed with a prompt excitation at 372nm, a 
prompt excitation monochromator of 372nm, and emissions monochromator of 435nm.  These 
are within the 20nm range of the maximum absorption and emission of the membrane probe 
TMA-DPH.  Excitation was provided by a 372nm Nano-LED light source.  The slit width was 
set to the widest setting at 32nm.  This was done to decrease the timeframe required to collect 
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10,000 counts.  Polarizers were programmed to collect data in the following positions: vertical-
vertical (V-V), vertical-horizontal (V-H), horizontal-horizontal (H-H), and horizontal-vertical 
(H-V).  These orientations are required in order to calculate the anisotropy value for a sample 
based on Equation 1 and Equation 3 in Chapter I in the section on TCSPC Anisotropy.  A 
solution of LUDOX specific for the IBH was used to zero the instrument to subtract light scatter.  
After initial data was collected, a short pass filter at 390nm was added and used on all 
subsequent experiments.  (See Results section Figure 13).  All data were analyzed and figures 
were created using a Microsoft Excel program.  
 
Treatments 
 Please refer to Table 1 for experimental design.  Treated cells were incubated with BMOV 
1 hour prior to imaging in concentrations ranging from 10µM to 0.1µM, and/or 200nM insulin.  
The fluorescent membrane probe, TMA-DPH, was applied in a 10µM concentration 10 minutes 
prior to imaging.  Cells were then harvested and counted via the cell counting protocol below.  
Cells were then imaged in a 9% Ficoll solution in 10mm quartz cuvettes at a concentration of 
1x10
^6
 cells/mL.  Control cells were only treated with 10µM TMA-DPH.  Within separate flasks, 
cells were labeled controls and for each treatment applied.  These flasks were imaged using the 
Zeiss Axiomat microscope in order to assess the health of the cells during the timeframe of data 















Addition of a short pass filter to the IBH apparatus for anisotropy measurements resulted 
in anisotropy values that were closer to the theoretical maximum allowed of 0.4 as seen in Figure 
13. 
In Figure 14, 200nM insulin caused an increase in anisotropy compared to untreated cells. 
10µM BMOV treated cells had a larger increase in anisotropy than when the cells were 
incubated with 10µM BMOV and 200nM insulin, but less than cells treated with insulin alone. 
In Figure 15, 200nM insulin again caused the largest increase in anisotropy compared to 
untreated cells.  1µM BMOV treated cells again had an increase in anisotropy compared to 
untreated cells, but had less effect than 200nM insulin.  1µM BMOV and 200nM insulin caused 
decreased anisotropy compared to untreated cells. 
In Figure 16, the largest increase in anisotropy was seen in 0.1µM BMOV compared to 
untreated cells.  Cells treated with 200nM insulin also demonstrated an increase in anisotropy 
over untreated cells but this was less than the effect of 0.1µM BMOV.  Cells treated with 0.1µM 
BMOV and 200nM insulin showed an increase in anisotropy over untreated cells but less than 




Figure 13. The effect of a 390nm short pass filter on TCSPC anisotropy measurements on 
RBL-2H3 cells.  The y-axis is anisotropy (r), and the x-axis is channel number.  Measurements 
were done until 10,000 counts of data had been collected.  NF indicates no filter was used in the 








Figure 14.  Experiment 1.  TCSPC Anisotropies of RBL-2H3 cells labeled with 10µM 










Figure 15.  Experiment 2.  TCSPC Anisotropies of RBL-2H3 cells labeled with 10µM 










Figure 16.  Experiment 3.  TCSPC Anisotropies of RBL-2H3 cells labeled with 10µM 




When first developing the method for measuring membrane fluidity in RBL-2H3 cells, a 
number of challenges arose.  Early in the development of this method using the IBH, we found 
that cells would begin to precipitate in solution.  To rectify this problem Ficoll was added to 
equal 9% of the cell solution.  Ficoll was chosen after absorption and emission spectra 
demonstrated that it does not absorb or emit within the spectrum of TMA-DPH (data not shown).  
The use of Ficoll kept the cells suspended for the duration of the experiments. 
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When analyzing the data from Figure 13, it is clear that there is a noticeable decrease in 
the maximal anisotropy with the addition of the 390nm short pass filter.  This filter was added to 
the IBH apparatus with the sole purpose of decreasing the amount of scattered light and cross-
talk that can occur in the fluorescing samples.  Given the improvement in the measurements 
following the addition of the short pass filter, it was included for the rest of the anisotropy 
measurements carried out on the cells. 
It is clear when looking at Figures 14-16 that there is a lack of consistency between each 
of the experiments as to which treatment resulted in the greatest increase in anisotropy.  An 
increase in anisotropy should correlate to a decrease in membrane fluidity due to an increase in 
lipid packing.  In Figures 14 and 15, 200nM insulin caused the greatest decrease in membrane 
fluidity, but in Figure 16 this treatment did not demonstrate the same effect.  Also of note, is that 
there was a marked decrease in anisotropy in Figure 15 in cells treated with both 0.1µM BMOV 
and 200nM insulin.  This would indicate that cells treated with 0.1µM BMOV + 200nM insulin 
actually resulted in an increase in membrane fluidity which would correlate with a loss of lipid 
packing.  
To explain the inconsistencies found in the above data, the cells that were left plated on 
the flasks but treated with the same treatments as those placed in the cuvettes for measurement in 
the IBH were imaged.  It was found that during the timeframe of the experiments, the cells were 
not able to maintain the 95% viability.  Cells began to show blebbing of their membranes which 
indicated cell stress and apoptosis.  In some flasks, cells had completely lost adhesion to the floor 
of the flasks and floated in the medium.  Samples from these flasks were taken and the cell 
counting protocol was performed.  Viable cells in these samples ranged from 10%-30% (data not 
41 
 
shown).  The loss of membrane integrity is the mostly explanation for the inconsistencies in the 
data. 
Concern for the viability of the cells was first raised when the first rounds of experiments 
were requiring hours of time to collect the 10,000 counts of photons set as our initial parameters.  
Steps were taken to optimize the parameters on the IBH and decrease the time needed to acquire 
10,000 counts.  However, prior to being able to decrease the timeframe of experiments, cells 
were reserved to be treated and observed under microscopy to evaluate viability.  It was also 
found that not only did the cell membrane integrity begin to fail as the viability of the cells 
decreased, but some samples demonstrated internalization of the TMA-DPH intracellularly (data 
not shown).  It was not clear whether this was a diffusive process, a loss of membrane integrity, 
or part of membrane cycling. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 Given the difficulties encountered with the cells due to the timescale of the experiments, 
it might be more advantageous to explore other methods of collecting membrane fluidity 
measurements.  One option is ratiometric imaging of a specific fluorophore such as Di-4-
ANEPPDHQ, which has a change in emission based on membrane lipid packing.  For example, 
its fluorescence emission is red at 605nm when the probe is restricted, but emission is green at 
530 nm when there is an increase in the viscosity of the probe’s environment.  This probe could 
potentially decrease the time required to collect data, thereby increasing the likelihood that the 
cells would still be living at the end of the experiments.  This would obviously allow for a more 
definitive discussion of the data and implications drawn from the data collected.  
 Other options exist for fluorophores to probe the PM.  These include Di-I C-18, PE, PC, 
DPH, and Di-O with each demonstrating an affinity for a specific portion of the membrane.  
Some preferentially stay in the hydrophobic section of the PM bilayer.  Others prefer either the 
cytoplasmic or extracellular leaflets of the membrane.  It would be of interest whether BMOV or 
other transition metal compounds specifically affect specialized membrane regions identified by 
these various probes. 
 All of the experiments were performed at 25°C.  Physiologic temperature is 37°C. For 
completeness, measurements at 4°, 15°, 25°, and 37°C should be completed.  Measurements at 
4°C were attempted but at this temperature, the lines carrying the cold water from the ice bath to 
the housing holding the cuvettes froze and the temperature was not  maintained even with 
insulation of water lines. 
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 As lipid peroxidation has been demonstrated to affect the insulin molecule, it would be 
interesting to know if the products of lipid peroxidation also affect the IR itself or its location in 
lipid raft fractions.  This could be done using a discontinuous sucrose gradient after treating cells 
with the oxidizing molecules described by Navarro and Pillon et al. (73,74).  Along these same 
lines, changes in the IR or the IR localization in response to exposure with the lipid peroxidation 
products is of interest as are effects of treatment with BMOV and other transition metals on the 
modified IR or lipid raft localization, or on the modified insulin molecule itself. 
 Given that ceramide is an intermediate for sphingomyelin degradation, it would be 
interesting to know what effect the lipid peroxidation products discussed above had on ceramide 
levels in treated and untreated cells and what effect, if any, BMOV and other transition metals 
had on ceramide levels.  
 Various compounds have demonstrated redox chemistry once the vanadium compounds 
reach the cell as well as during transport through the body.  Investigation of the potential for 
redox reactions between lipid peroxidation products and vanadium species would be prudent.  
Such a mechanism would explain lipid and glucose normalization properties of some vanadium 
complexes. 
 Of note is the link between the metabolic derangements discussed and fertility, 
specifically with respect to Polycystic Ovarian Syndrome (PCOS).  Patients with this syndrome 
typically have obesity, insulin resistance, hirsutism, elevated levels of aldosterone, irregular 
menses, and issues with infertility.  The relationship between increased aldosterone levels and 
insulin resistance has not been elucidated (133).  It would be interesting to see if BMOV or other 
transition metal compounds are able to affect aldosterone production, or if they exert an effect on 
other hormones regulating the menstrual cycle such as estrogen, follicle stimulating hormone 
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(FSH) and luteinizing hormone (LH).  It would also be interesting to know if there is any change 
in the aldosterone molecule secondary to the effects of ROS or toxic metabolites of PM lipid 
peroxidation as described in the insulin molecule by Navarro and Pillon (73,74).  
 All of the above experiments would be performed on RBL-2H3 cells.  It would also be 
prudent to know how adipocytes, specifically 3T3-L1 adipocytes, which have been well 
characterized, respond to treatment with vanadium and other transition metal compounds.  For 
experiments investigating transition metal compounds and PCOS, in addition to adipocytes, 
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LIST OF ABBREVIATIONS 
 
3T3-L1:              cell line of adipocytes 
Akt:                    serine/threonine specific kinase, also known as PKB  
APS:                   Cbl binding protein  
BEOV:               bis(ethylmaltolato)oxovanadium (IV) complex  
BMOV:              bis(maltolato)oxovanadium(IV) complex 
C3G:                  guanine nucleotide exchange factor 
CAP  :                cyclase associated protein  
c-Cbl:                 E3 ubiquitin-protein ligase adaptor molecule 
CDase:               ceramidase 
DAG                  diacylglycerol 
EDTA:               ethylenediamine tetraacetic acid  
FABP:                fatty acid binding protein 
Fas:                    cell surface receptor which signals cell death 
FBS:                   fetal bovine serum  
FFA:                   free fatty acid  
FKHR:               transcription factor “forkhead in human rhabdomyosarcoma” (FOXO1a) 
FSH:                   follicle stimulating hormone 
GLUT4:             glucose transporter 4 
GM-3:                a subset of ganglioside 
GPx :                  glutathione peroxidase 
GSK3:                glycogen synthase kinase 3, a serine threonine kinase 
HDL:                  high density lipoprotein 
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IBH:                   fluorometer manufactured by Jovin Horiba 
IGF-1:                insulin-like growth factor-1 
IGF-2                 insulin-like growth factor-2 
IKKβ:                 inhibitor of nuclear factor kappa-B kinase 
IR:                      insulin receptor 
IRS-1:                insulin receptor substrate 1 
JNK:                  c-Jun N-terminal kinase 
LDL:                  low density lipoprotein 
LH:                     luteinizing hormone 
LO:                     liquid ordered 
MD:                   microdomain 
MEM:                Minimum Essential Medium  
mRNA:              messenger ribonucleic acid 
NEFA:               non-esterified fatty acid 
NFκB:                nuclear factor kappa-light-chain-enhancer of activated B cells  
OS:                     oxidative stress 
PI3K:                  phosphatidylinositol 3-kinase  
P70S6K:             p70 ribosomal S6  kinase 
PBS:                   phosphate buffered saline 
PC:                     phosphatidylcholine 
PCOS:                polycystic ovarian syndrome 
PE                      phosphatidylethanolamine 
PIP2:                  phosphatidylinositol-4 5-bisphosphate 
55 
 
PIP3:                  phosphatidylinositol (3,4,5)-triphosphate 
PKB:                  protein kinase B 
PKC:                  protein kinase C 
PM:                    plasma membrane 
PP1:                    protein phosphatase 1 (class of serine/threonine phosphatase) 
PPAR:                peroxisome proliferator-activated receptors 
PS:                      phosphatidylserine 
PSA:                   penicillin + streptomycin +amphotericin B  
PTPase:              protein tyrosine phosphatase 
Rac:                    subset of Rho family GTPases 
RBL-2H3:          rat basophilic leukemia cell line 
RNA:                  ribonucleic acid 
RNS:                  reactive nitrogen species 
ROS:                  reactive oxygen species 
S1P                     sphingosine 1-phosphate 
Ser:                     serine 
SER:                   smooth endoplasmic reticulum 
SH2:                   Src homology 2 domain 
Shc:                    Src homology domain containing 
SHIP2:               SH2 domain containing inositol 5-phosphatase 2 
SM:                    sphingomyelin 
SMase:               sphingomyelinase 
SREBP-1:          Sterol regulatory element-binding protein-1 
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TC10:                 protein member of Rho family of GTPases 
TG:                     triglyceride 
Thr:                    threonine 
TMA-DPH:        1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p-toluenesulfonate 
TNF-α:               tumor necrosis factor-alpha 
VO2dipic:           dipicolinatooxovanadium(V) 
 
 
 
 
 
